Literature DB >> 26339405

Relationship between the single nucleotide polymorphisms of β₂-adrenergic receptor 5'-regulatory region and essential hypertension in Chinese Kazakh ethnic minority group.

Weijuan Cai1, Liang Yin2, Jiang Cheng1, Shaoliang Wang1, Yu Wei1, Wenjiang Cao1, Jiang Cheng1.   

Abstract

OBJECTIVE: To study the correlation of β2-AR gene 5'-regulatory region SNPs and essential hypertension (EH) in Chinese Kazakh ethnic minority group.
METHODS: The Sequenom MassArray(®) SNP detection technology was used to detect β2-AR gene 5'-regulatory region SNPs in 150 Xinjiang Kazakh EH patients and 150 controls. Biochemical analyzer was used to detect lipid and other related biochemical parameters. SHEsis and other software were used to analyze linkage disequilibrium and haplotype.
RESULTS: Six loci rs205304 (-1023G/A), rs17108803 (-893T/G), rs12654778 (-654G/A), rs11168070 (-468C/G), rs11959427 (-367C/T) and rs2895795 (-1429T/A) polymorphisms of β2-AR gene 5'-regulatory region were found in the Xinjiang Kazakh populations. While, there was no significant difference between EH group and NH in genotypes and allele frequency of rs2053044, rs12654778, rs2895795, rs17108803 and rs11959427 (P>0.05). However; significant differences were detected of rs11168070 genotypes and allele frequency in two groups (P<0.05). Analysis of the linkage disequilibrium and haplotype in Kazakh population, there is a strong linkage disequilibrium of rs11168070, rs2053044, rs2895795 gene polymorphism in the EH group, and rs11168070, rs12654778, rs17108803 gene polymorphism in controls. Frequency of haplotype GTCCAT, GACTGT and ATGCGT in EH group was higher (P<0.05), while frequency of ATCTGT, ATGTGT, GTCCGT, GTCTAT, GACCAT and GTCTGT in the EH group was significantly lower than the control (P<0.05).
CONCLUSIONS: β2-AR gene 5'-regulatory region of rs11168070, rs2053044, rs17108803, rs12654778, rs11959427 and rs2895795 genetic polymorphism exists in Kazakh. Among them, rs11168070 locus genotype and allele frequency distribution in the two groups are significant differences. In six polymorphic loci, there is a strong linkage disequilibrium, which haplotypes GTCCAT, GACTGT, ATGCGT are risk factors of EH, and the ATCTGT, ATGTGT, GTCCGT, GTCTAT, GACCAT, GTCTGT are protective factors.

Entities:  

Keywords:  Kazakh; gene polymorphism; hypertension; β2-adrenergic receptor

Mesh:

Substances:

Year:  2015        PMID: 26339405      PMCID: PMC4555733     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  11 in total

1.  Essential hypertension and beta2-adrenergic receptor gene: linkage and association analysis.

Authors:  Maciej Tomaszewski; Nick J R Brain; Fadi J Charchar; William Y S Wang; Beata Lacka; Sandosh Padmanabahn; James S Clark; Niall H Anderson; Helen V Edwards; Ewa Zukowska-Szczechowska; Wladyslaw Grzeszczak; Anna F Dominiczak
Journal:  Hypertension       Date:  2002-09       Impact factor: 10.190

2.  Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade.

Authors:  F Filigheddu; J E Reid; C Troffa; P PinnaParpaglia; G Argiolas; A Testa; M Skolnick; N Glorioso
Journal:  Pharmacogenomics J       Date:  2004       Impact factor: 3.550

3.  Association analysis of beta(2)-adrenergic receptor polymorphisms with hypertension in Japanese.

Authors:  N Kato; T Sugiyama; H Morita; H Kurihara; T Sato; Y Yamori; Y Yazaki
Journal:  Hypertension       Date:  2001-02       Impact factor: 10.190

4.  Polymorphisms of the beta2 -adrenoceptor (ADRB2) gene and essential hypertension: the ECTIM and PEGASE studies.

Authors:  Stefan-Martin Herrmann; Viviane Nicaud; Laurence Tiret; Alun Evans; Frank Kee; Jean-Bernard Ruidavets; Dominique Arveiler; Gerald Luc; Caroline Morrison; Margret R Hoehe; Martin Paul; François Cambien
Journal:  J Hypertens       Date:  2002-02       Impact factor: 4.844

5.  beta2-adrenoceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians.

Authors:  H Jia; P Sharma; R Hopper; C Dickerson; D D Lloyd; M J Brown
Journal:  J Hypertens       Date:  2000-06       Impact factor: 4.844

6.  Human beta2-adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans.

Authors:  H G Xie; C M Stein; R B Kim; J V Gainer; G Sofowora; V Dishy; N J Brown; R E Goree; J L Haines; A J Wood
Journal:  Clin Pharmacol Ther       Date:  2000-06       Impact factor: 6.875

7.  Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.

Authors:  David E Lanfear; Philip G Jones; Sharon Marsh; Sharon Cresci; Howard L McLeod; John A Spertus
Journal:  JAMA       Date:  2005-09-28       Impact factor: 56.272

Review 8.  Hypertension: genes and environment.

Authors:  P Hamet; Z Pausova; V Adarichev; K Adaricheva; J Tremblay
Journal:  J Hypertens       Date:  1998-04       Impact factor: 4.844

9.  beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension.

Authors:  M A Pacanowski; Y Gong; R M Cooper-Dehoff; N J Schork; M D Shriver; T Y Langaee; C J Pepine; J A Johnson
Journal:  Clin Pharmacol Ther       Date:  2008-07-09       Impact factor: 6.875

10.  The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker.

Authors:  Orly Vardeny; Michelle A Detry; John J M Moran; Maryl R Johnson; Nancy K Sweitzer
Journal:  J Cardiovasc Pharmacol       Date:  2008-12       Impact factor: 3.105

View more
  2 in total

1.  Association between ADRB2 regulatory region polymorphisms and susceptibility to childhood asthma.

Authors:  Ming-Xuan Cai; Bing Wei; Shi-E Liao; Jin-Yue Fu; Ya-Jun Liu; Ling-Xue Li
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2021-11-15

2.  A functional SNP upstream of the ADRB2 gene is associated with COPD.

Authors:  Jin-Xiu Li; Wei-Ping Fu; Jing Zhang; Xiao-Hua Zhang; Chang Sun; Lu-Ming Dai; Li Zhong; Li Yu; Ya-Ping Zhang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-03-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.